IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 49.8% in September

Key Points

• IceCure Medical Ltd. experienced a significant decline in short interest, dropping 49.8% in September, with total short interest amounting to 577,300 shares.
• The company's stock price was $0.96 as of recent trading, with a one-year low of $0.48 and a high of $1.66.
• Analysts have assigned a consensus rating of "Moderate Buy" for IceCure Medical, with a target price of $2.39.

IceCure Medical Ltd. (NASDAQ:ICCM - Get Free Report) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 577,300 shares, a drop of 49.8% from the August 31st total of 1,150,000 shares. Currently, 1.7% of the company's stock are short sold. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.7% of the company's stock are short sold.

IceCure Medical Stock Performance

Shares of IceCure Medical stock traded down $0.03 on Friday, hitting $0.96. 15,681,815 shares of the company's stock were exchanged, compared to its average volume of 1,007,560. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.88 and a current ratio of 1.18. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.66. The company has a 50-day simple moving average of $0.98 and a 200-day simple moving average of $1.04. The stock has a market capitalization of $66.23 million, a PE ratio of -6.03 and a beta of 0.31.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The company had revenue of $0.66 million for the quarter, compared to analysts' expectations of $0.90 million. As a group, equities analysts anticipate that IceCure Medical will post -0.28 EPS for the current year.

Analyst Upgrades and Downgrades

ICCM has been the subject of several analyst reports. Wall Street Zen downgraded shares of IceCure Medical from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Loop Capital set a $2.77 target price on shares of IceCure Medical in a research report on Wednesday, August 13th. Brookline Capital Management reaffirmed a "buy" rating on shares of IceCure Medical in a research report on Wednesday, August 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of IceCure Medical in a research report on Saturday, September 27th. Finally, Zacks Research downgraded shares of IceCure Medical from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, IceCure Medical presently has a consensus rating of "Moderate Buy" and a consensus target price of $2.39.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.